Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug 24:11:726785.
doi: 10.3389/fonc.2021.726785. eCollection 2021.

Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect

Umair Majeed  1 , Tudor Puiu  2 , Jason Sluzevich  2 , Gina Reynolds  1 , Marites Acampora  1 , Alvaro Moreno-Aspitia  1 , Katherine J Bodiford  2 , Pooja Advani  1
Affiliations
Case Reports

Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect

Umair Majeed et al. Front Oncol. .

Abstract

Alpelisib is a PIK3a inhibitor approved for the treatment of metastatic ER+ breast cancer in combination with fulvestrant. Although rash is a common side effect of this medication, we present the first case of drug reaction with eosinophilia and systemic symptoms (DRESS) upon initial exposure to alpelisib. Here we describe the clinical-pathological findings and management of our patient with alpelisib-induced life-threatening DRESS syndrome. The goal of this case report is to highlight association of alpelisib with DRESS syndrome, in clinical practice, so that alpelisib can be immediately stopped and treatment for this serious condition promptly initiated.

Keywords: DRESS; PI3K inhibitor therapy; alpelisib; breast cancer; drug rash.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A–C) Rash on the back, legs, and abdomen at presentation, (D–F) Rash on the back, legs, and abdomen after steroid treatment.
Figure 2
Figure 2
H and E stain of right lower abdomen punch biopsy showing focal epidermal dyskeratosis, mild spongiosis, and moderate vacuolar interface dermatitis in association with superficial perivascular lymphohistocytic inflammation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. . Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): An Original Multisystem Adverse Drug Reaction. Results From the Prospective RegiSCAR Study. Br J Dermatol (2013) 169(5):1071–80. 10.1111/bjd.12501 - DOI - PubMed
    1. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the Number of Women Living With Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev (2017) 26(6):809–15. 10.1158/1055-9965.EPI-16-0889 - DOI - PMC - PubMed
    1. Sheth M, Demchok JA, Mills Shaw KR, Yang L, Eley G, Ferguson ML, et al. . Comprehensive Molecular Portraits of Human Breast Tumours. Nature (2012) 490(7418):61–70. 10.1038/nature11412 - DOI - PMC - PubMed
    1. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. . Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials. Mol Cancer Ther (2014) 13(5):1117–29. 10.1158/1535-7163.MCT-13-0865 - DOI - PubMed
    1. Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, et al. . FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients With HR-Positive, HER2-Negative, PIK3CA-Mutated, Advanced or Metastatic Breast Cancer. Clin Cancer Res (2021) 27(7):1842–9. 10.1158/1078-0432.CCR-20-3652 - DOI - PMC - PubMed

Publication types

LinkOut - more resources